Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Daiichi Sankyo’s Valemetostat Logs 48% Response in Japan ATL Study
Daiichi Sankyo said on December 11 that its EZH1/2 dual inhibitor valemetostat met the primary goal in a Japanese PII study for the treatment of relapsed/refractory adult T-cell leukemia-lymphoma (ATL). The drug, also known as DS-3201, delivered an objective response…
To read the full story
Related Article
- Daiichi Sankyo’s EZH1/2 Inhibitor Filed for ATL in Japan
January 5, 2022
- Daiichi Sankyo, France/Belgium Lymphoma Group to Collaborate on Valemetostat Trial
February 26, 2021
- 1st Patient Dosed in Japan PII for Daiichi Sankyo’s ATL Drug
December 11, 2019
BUSINESS
- Shionogi, Susmed End Sales Partnership for Insomnia App
August 27, 2026
- Nxera to Earn US$10 Million Milestone as Alzheimer’s Candidate Moves to PII
August 27, 2026
- Takeda’s XFG-Targeted COVID Jab Approved in Japan
August 27, 2026
- Meiji Wins Japan Approval for NB.1.8.1-Adapted COVID Vaccine
August 27, 2026
- Japan Pharma Market Seen Topping 11 Trillion Yen by 2035: Fuji Keizai
August 26, 2026
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…